Perifosine

DB06641InvestigationalSmall molecule

Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.

Mechanism: Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth. This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.
Curator reviewed
Primary indication: Investigated for use/treatment in solid tumors, multiple myeloma, leukemia (unspecified), lung cancer, and brain cancer.Curator reviewed
Formula / weight: C₂₅H₅₂NO₄P · 461.668 g/mol (avg)
Code names: KRX-0401 · NSC-639966

Resolves to

Compound

Structure

InChIKeySZFPYBIJACMNJV-UHFFFAOYSA-NSMILESCCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1

Targets

What you can answer from here — as of January 29, 2025

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

38Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Perifosine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.